Veracyte Receives Regulatory Authorization to Offer Percepta Bronchial Genomic Classifier for Patients in New York State

Veracyte, Inc. VCYT today announced that it has received regulatory authorization from the New York State Department of Health to offer the Percepta™ Bronchial Genomic Classifier for patients in the state. The genomic test, commercially introduced in April 2015, is used to help patients avoid unnecessary invasive, risky and costly procedures to assess potentially cancerous lung nodules that were initially found on CT scans. "We are delighted that the Percepta Bronchial Genomic Classifier will now be available to physicians and their patients in New York State," said Bonnie Anderson, Veracyte's president and chief executive officer. "This significant milestone underscores the clinical need for and strength of the validation data supporting our test. We look forward to offering the Percepta test in New York State as we continue its initial rollout to select institutions around the country." The Percepta Bronchial Genomic Classifier comprises a 23-gene test that uses proprietary technology to identify patients with lung nodules or lesions who are at low risk of cancer following an inconclusive bronchoscopy result, so that they See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!